GlassScriptPhysician profile
Ashton L Fox
NPI 1568196616
$1,578.43
in general payments reported to CMS, 2019-2025
22 companies · $889 in 2025
The $889 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $45.40 · 2023: $389 · 2024: $255 · 2025: $889.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,533.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,533.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $500.77 | 2023-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $245.57 | 2022-2024 | Jornay Pm |
| Corium, LLC | $219.52 | 2023-2025 | Azstarys |
| Lnhc, INC | $115.10 | 2025 | Zelsuvmi |
| Collegium Pharmaceutical, INC. | $60.43 | 2025 | Jornay Pm |
| Sanofi Pasteur INC. | $53.98 | 2025 | |
| Krystal Biotech INC | $43.21 | 2024 | Vyjuvek |
| Cranial Technologies, INC | $38.26 | 2025 | Doc Band |
| Tris Pharma INC | $35.64 | 2025 | Onyda Xr |
| Aytu Biopharma, INC. | $32.85 | 2025 | |
| Merck Sharp & Dohme LLC | $28.65 | 2023-2024 | Vaxneuvance, Gardasil 9, Vaxelis |
| Ars Pharmaceuticals Operations, INC. | $26.90 | 2025 | Neffy |
| Noven Therapeutics, LLC | $20.42 | 2025 | Xelstrym |
| Cipher Pharmaceuticals US LLC | $20.28 | 2025 | Natroba, Spinosad |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $19.37 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $18.73 | 2025 | |
| Verrica Pharmaceuticals INC. | $18.56 | 2025 | Ycanth |
| Astrazeneca Pharmaceuticals LP | $16.73 | 2023 | Flumist Quadrivalent |
| Neos Therapeutics, LP | $16.64 | 2023 | Cotempla Xr-Odt |
| Seqirus USA INC | $16.49 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $15.37 | 2025 | Kristalose |
| Pfizer INC. | $14.96 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashton Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.